



Press release

For immediate distribution

OrganOx, a Life-Saving Medical Device Company Transforming Organ Transplantation, Has Raised a £25m Growth Round led by Lauxera Capital Partners

- **Founded in 2008 and based in Oxford, England, OrganOx’s technology enables hospitals to transplant more organs and reduce the volume of transplantation surgeries performed during the night.**
- **Since inception, the company’s award-winning Normothermic Machine Perfusion (NMP) technology has supported over 2,500 liver transplants worldwide.**
- **Lauxera’s investment will enable OrganOx to continue driving topline growth through its commercial partnerships with leading transplant centers in the United States and Europe.**

Paris (France), Oxford (United Kingdom), San Francisco (USA), July 17 2023 – Lauxera Capital Partners has led a £25m growth investment into OrganOx, a commercial-stage, Oxford, England-based medical device company. OrganOx develops and commercializes organ preservation and transportation devices designed to directly save lives by increasing the supply of organs available for transplantation.

OrganOx was founded in 2008 by two renowned Oxford University Professors, Peter Friend (Professor of Surgery) and Constantin Coussios (Professor of Biomedical Engineering), as an academic spinoff from Oxford University. OrganOx’s device, *metra*, preserves donor livers and enables assessment of the organs prior to transplantation reducing organ discard and allowing surgeons to perform transplantations during the working day rather than as an emergency at night.

OrganOx’s mission is to increase the number of organs available for transplantation. Its *metra* device seeks to re-create an environment for the recovered liver that mimics the human body. In the machine, livers are continuously perfused at physiological pressures using oxygen-carrying red blood cells. The core technology employed by *metra* has been in development for over 15 years and the device is FDA approved for liver preservation. The company’s technology for kidney transplantation is in human clinical trials.

Over 2,500 liver transplants supported throughout the world

metra’s rapid growth has been driven by the technology’s ability to objectively assess a donor organ allowing surgeons to confidently transplant “marginal” livers that might otherwise have been discarded. Donor liver preservation and assessment with the *metra* has resulted in over 50% fewer

liver discards and 20% more transplanted livers, compared with static cold storage, according to a recent, randomized European trial.

Utilization of machine perfusion prior to liver transplantation makes the surgery safer by reducing the risk of recipient hypotension and cardiac arrest on the operating table. As *metra* offers up to 24 hours of preservation time, NMP also enables surgeons to avoid operating overnight. Avoiding night operations reduces surgical complications and makes a career in transplant surgery more sustainable.

Lauxera's investment will enable OrganOx to radically expand its commercial footprint, build new manufacturing facilities, and conduct a broad array of post-market clinical evaluations.

Craig Marshall, CEO of OrganOx, said: *"Organ transplantation saves and radically improves lives. Approximately 100,000 men, women and children in the United States are on the national transplant waiting list with a new patient added every ten minutes. OrganOx is committed to using our Normothermic Machine Perfusion technology to make organs more widely available to patients who need them around the world. We are thrilled at the prospect of working closely with Lauxera to take OrganOx to new heights in the US and ROW"*

Oern Stuge MD,MBA, Executive Chairman of OrganOx said *"This investment from Lauxera represents a diversification of the Company's cap table and is an important step in the direction of getting ready for a potential future IPO"*

Samuel Levy, Founding Partner of Lauxera Capital Partners, added: *"Although more than 9,000 liver transplants are performed each year in the United States, more than 1,500 people die each year waiting for a liver on the transplant list. This represents only ~3% of the 50,000 Americans who die each year from liver failure. This is unacceptable. Lauxera is proud and honored to back the OrganOx team and its global commercial scale up."*

This is the ninth investment made by Lauxera Growth I, a growth and growth buy-out fund dedicated to investing in commercial-stage European and North American HealthTech businesses.

Hogan Lovells served as legal counsel on the transaction. D'Ornano + Co. served as advisor on certain legal, tax, and financial due diligence matters. MD Compliance advised the firm on Manufacturing & Supply chain matters and Levine Bagade Han LLP advised the firm on Intellectual Property due diligence matters.

About Lauxera Capital Partners

Founded in January 2020, Lauxera Capital Partners is an independent asset management company based in France (Paris) and in the United States (San Francisco). Lauxera is a healthcare specialist investor working to promote the growth of European HealthTech companies. Its first fund, Lauxera Growth I, was reserved for professional investors and obtained the French government's "Tibi" label within the framework of the institutional investors' charter for the financing of technology companies. Led by a team of life sciences business builders and professional healthcare investors with more than 50 years' experience, Lauxera aims to support the international commercial expansion of Europe's most promising HealthTech innovations.

More information on: <https://lauxera.com/fr/>

About OrganOx and *metra*

Based in Oxford, UK, OrganOx is a world leader in normothermic machine perfusion, dedicated to saving lives by making every donated organ count. The multi-award winning OrganOx *metra* uses proprietary NMP technology to preserve donor livers in a functioning state for up to 24 hours prior to transplant.

metra is a fully automated NMP device that enables continuous monitoring and evaluation of the liver, empowering surgeons to make evidence-based decisions on whether to transplant a donor organ, enabling viability testing and transplant of previously declined organs. *metra* is commercially available in Europe (CE Mark) and the United States (FDA Approved: P200035).

For more information, please visit our website: organox.com

Press contacts:

Ulysse Communication

Bruno ARABIAN

+33 (0) 6 87 88 47 26 barabian@ulyse-communication.com

Charles COURBET

+33 (0)6 28 93 03 06 ccourbet@ulyse-communication.com

OrganOx

Joanna BRIGHT

+44 (0) 1865 504024 marketing@organox.com